Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
8 results
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, Volume 27, Issue 11, 1 1 2019, Pages 550-558 Myocardial infarction patients referred to the primary care physician after 1‑year treatment according to a guideline-based protocol have a good prognosis. Bodde MC, van Hattem NE, Abou R, Mertens BJA, van Duijn HJ, Numans ME, Bax JJ, Schalij MJ, Jukema JW
Introduction: Identifying ST-elevation myocardial infarction (STEMI) patients who can be referred back to the general practitioner (GP) can improve patient-tailored care. However, the long-term prognosis of patients who are returned to the care of their GP is unknown. Therefore, the aim of this study was to assess the long-term prognosis of patients referred back to the GP after treatment in accordance with a 1-year institutional guideline-based protocol. Methods: All consecutive patients treate... Abstract
Cited 1 times since 2019 (0.2 per year) source: EuropePMC
Cardiology and therapy, Volume 8, Issue 1, 13 2 2019, Pages 55-67 Plasma LDL-Cholesterol Level at Admission is Independently Associated with Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. Bodde MC, Hermans MPJ, Wolterbeek R, Cobbaert CM, van der Laarse A, Schalij MJ, Jukema JW
Introduction: Hypercholesterolemia is a well-known risk factor for developing atherosclerosis and subsequently for the risk of a myocardial infarction (MI). Moreover, it might also be related to the extent of damaged myocardium in the event of a MI. The aim of this study was to evaluate the association of baseline low density lipoprotein-cholesterol (LDL-c) level with infarct size in patients with ST-segment elevation myocardial infarction (STEMI) after primary percutaneously coronary interventi... Abstract
Cited 6 times since 2019 (1.1 per year) source: EuropePMC
Cardiology and therapy, Volume 8, Issue 1, 30 5 2019, Pages 29-41 Growth Differentiation Factor-15 Levels at Admission Provide Incremental Prognostic Information on All-Cause Long-term Mortality in ST-Segment Elevation Myocardial Infarction Patients Treated with Primary Percutaneous Coronary Intervention. Bodde MC, Hermans MPJ, van der Laarse A, Mertens B, Romijn FPHTM, Schalij MJ, Cobbaert CM, Jukema JW
Introduction: To investigate the additive prognostic value of growth differentiation factor (GDF-15) levels in ST-segment elevation myocardial infarction (STEMI) patients treated with primary percutaneously coronary intervention (pPCI) with 10-year mortality on top of clinical characteristics and known cardiac biomarkers. Methods: Baseline serum GDF-15 levels were measured in 290 STEMI patients treated with pPCI in the MISSION! intervention trial conducted from February 1, 2004 through October 3... Abstract
Cited 23 times since 2018 (4.1 per year) source: EuropePMC
Clinical research in cardiology : official journal of the German Cardiac Society, Volume 108, Issue 5, 8 2 2018, Pages 520-538 Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. Bodde MC, Hermans MPJ, Jukema JW, Schalij MJ, Lijfering WM, Rosendaal FR, Romijn FPHTM, Ruhaak LR, van der Laarse A, Cobbaert CM
Introduction: The current way to assess the risk of cardiovascular disease (CVD) is to measure conventional lipid and lipoprotein cholesterol fractions. Despite the success of statin treatment, residual cardiovascular risk remains high. Therefore, the value of extensive serum apolipoprotein (apo) profiling to assess the risk of ST-segment elevation myocardial infarction (STEMI) and of major adverse cardiac events (MACE) in patients with STEMI was investigated in a case-control design. Methods an... Abstract
Cited 2 times since 2018 (0.3 per year) source: EuropePMC
Clinical pharmacology and therapeutics, Volume 104, Issue 2, 15 3 2018, Pages 311-316 A Rapid (Differential) Effect of Rosuvastatin and Atorvastatin on High-Sensitivity Cardiac Troponin-I in Subjects With Stable Cardiovascular Disease. Bodde MC, Welsh P, Bergheanu SC, Lijfering WM, Mertens B, Liem AH, van der Laarse A, Sattar N, Jukema JW
Serum troponin within the normal range is an emerging predictor of cardiovascular mortality. We aimed to determine how rapidly high-sensitivity troponin-I (hs-cTnI) levels are lowered by statin therapy in patients with stable cardiovascular disease. In the RADAR substudy, patients were randomized to atorvastatin 20 mg/day (n = 39) or rosuvastatin 10 mg/day (n = 39) and up-titrated at 6-week intervals to 80 mg of atorvastatin or 40 mg of rosuvastatin. Hs-cTnI concentrations were measured at basel... Abstract
Cited 5 times since 2017 (0.7 per year) source: EuropePMC
Journal of clinical lipidology, Volume 11, Issue 6, 8 2 2017, Pages 1407-1414 Low levels of apolipoprotein-CII in normotriglyceridemic patients with very premature coronary artery disease: Observations from the MISSION! Intervention study. Hermans MPJ, Bodde MC, Jukema JW, Schalij MJ, van der Laarse A, Cobbaert CM
Background: While the overall acute myocardial infarction rates declined in women and men, premature acute myocardial infarction rates remained stable in men and increased in women. Objective: The purpose of this study was to assess whether baseline apolipoprotein (apo) levels, clinical characteristics, and follow-up of patients with very premature coronary artery disease (CAD) could provide novel clues for the identification of high-risk individuals. Methods: Apos were measured with a validated... Abstract
Cited 95 times since 2017 (13.4 per year) source: EuropePMC
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, Volume 25, Issue 4, 1 1 2017, Pages 231-242 Pathophysiology and treatment of atherosclerosis : Current view and future perspective on lipoprotein modification treatment. Bergheanu SC, Bodde MC, Jukema JW
Recent years have brought a significant amount of new results in the field of atherosclerosis. A better understanding of the role of different lipoprotein particles in the formation of atherosclerotic plaques is now possible. Recent cardiovascular clinical trials have also shed more light upon the efficacy and safety of novel compounds targeting the main pathways of atherosclerosis and its cardiovascular complications.In this review, we first provide a background consisting of the current unders... Abstract
Cited 18 times since 2012 (1.6 per year) source: EuropePMC
Atherosclerosis, Volume 227, Issue 1, 24 4 2012, Pages 95-99 Determinants of calcification growth in atherosclerotic carotid arteries; a serial multi-detector CT angiography study. van Gils MJ, Bodde MC, Cremers LG, Dippel DW, van der Lugt A
Background: Little is known about the natural course of atherosclerotic plaque in the carotid artery bifurcation. This study investigated the growth pattern of calcifications in atherosclerotic carotid arteries and its determinants using serial multi-detector CT angiography (MDCTA). Methods: From a cohort of consecutive patients with TIA or ischemic stroke and a baseline MCDTA scan of the carotid arteries, subjects were invited for a follow-up scan after 4-6 years. Calcification volumes were sco... Abstract